港股异动 | 澳优(1717.HK)涨超6% 前三季度纯利同比增长14%
格隆汇11月12日丨澳优(1717.HK)低开高走,现报11.14港元,涨6.1%,暂成交974万港元,最新总市值191亿港元。澳优昨日晚间公布,截至9月30日止9个月,公司收益57.576亿元(人民币,下同),同比增长22.8%;毛利29.06亿元,同比增长19.1%;公司拥有人应占净利润7.12亿元,同比增长14%。公告称,集团自家品牌配方牛奶粉及其他业务截至9月30日止3个月的收入增长率相比上一季有所改善。第三季,集团自家品牌配方牛奶粉的收入继续大幅增长。销售额增长是由于集团推行的营销策略继续行之有效,以及继续受惠于中国持续产品升级及市场细分化的趋势。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.